Stifel Nicolaus Begins Coverage on Verve Therapeutics (NASDAQ:VERV)

Stifel Nicolaus initiated coverage on shares of Verve Therapeutics (NASDAQ:VERV) in a report issued on Thursday, Price Targets.com reports. The brokerage issued a hold rating and a $58.00 price target on the stock.

VERV has been the topic of several other reports. JPMorgan Chase & Co. assumed coverage on shares of Verve Therapeutics in a report on Monday, July 12th. They set a neutral rating and a $50.00 price objective on the stock. Guggenheim initiated coverage on shares of Verve Therapeutics in a report on Monday, July 12th. They issued a buy rating and a $84.00 price target on the stock. William Blair restated a buy rating on shares of Verve Therapeutics in a report on Thursday, September 2nd. Finally, Jefferies Financial Group initiated coverage on shares of Verve Therapeutics in a report on Monday, July 12th. They issued a buy rating and a $72.00 price target on the stock. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Buy and a consensus target price of $71.20.

Shares of VERV stock opened at $47.93 on Thursday. Verve Therapeutics has a 1-year low of $29.50 and a 1-year high of $78.00. The business’s 50-day moving average is $62.13.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings data on Thursday, August 12th. The company reported ($2.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($1.60). As a group, research analysts anticipate that Verve Therapeutics will post -0.35 earnings per share for the current year.

A number of large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in Verve Therapeutics in the second quarter valued at approximately $411,000. Marshall Wace North America L.P. acquired a new stake in Verve Therapeutics in the second quarter valued at approximately $1,112,000. Morgan Stanley acquired a new stake in Verve Therapeutics in the second quarter valued at approximately $149,000. Woodline Partners LP acquired a new stake in shares of Verve Therapeutics during the second quarter worth approximately $12,467,000. Finally, Logos Global Management LP acquired a new stake in shares of Verve Therapeutics during the second quarter worth approximately $45,685,000. 55.59% of the stock is owned by institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.

Featured Story: ESG Score

Analyst Recommendations for Verve Therapeutics (NASDAQ:VERV)

Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.